SCHEMBL19873696

SCHEMBL19873696

O=C(O)CCCn1c(=O)[nH]cc(-c2cccc(F)c2Cl)c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.44
HSD17B10 Q99714 2/20 0.44
MAPK1 P28482 1/20 0.44
FABP4 P15090 2/20 0.39
FABP5 Q01469 2/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
CYP3A4 P08684 3/20 0.37
GNRHR P30968 3/20 0.37
CHEK1 O14757 1/20 0.36
WEE1 P30291 1/20 0.36
ALDH1A1 P00352 4/20 0.35
HPGD P15428 1/20 0.35
APEX1 P27695 1/20 0.35
POLB P06746 1/20 0.34
FPR1 P21462 1/20 0.34
FPR2 P25090 1/20 0.34
HTT P42858 2/20 0.33
MAP3K5 Q99683 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21900258 0.93 APEX1 (0.42) KDM4EHSD17B10MAPK1FABP4FABP5
SCHEMBL21900230 0.86 FPR1 (0.41) KDM4EMEN1KMT2AAPEX1FPR1
SCHEMBL28645646 0.82 CHEK1 (0.38) KDM4ECYP3A4GNRHRCHEK1WEE1
SCHEMBL17870766 0.81 KDM4E (0.32) KDM4EMEN1KMT2ACYP3A4GNRHR
SCHEMBL30178654 0.81 KDM4E (0.32) KDM4EMEN1KMT2ACYP3A4GNRHR
SCHEMBL30178581 0.79 CCNE2 (0.34) KDM4EMEN1KMT2AGNRHRALDH1A1
SCHEMBL19873988 0.79 APAF1 (0.36) CYP3A4GNRHRPOLBFPR1FPR2
SCHEMBL17870754 0.78 CCNE2 (0.33) CYP3A4GNRHRCCNE2CCNE1CDK2
SCHEMBL12657640 0.77 KDM4E (0.49) KDM4EHSD17B10MAPK1FABP4FABP5
SCHEMBL28641642 0.77 KDM4E (0.45) KDM4EHSD17B10ALDH1A1POLBFPR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107428744-B Novel heterocyclic compounds and their use in medicine and cosmetics 盖尔德马研究及发展公司 2021-09-24 CN disclosed
US-10246422-B2 Heterocyclic compounds and use thereof in medicine and in cosmetics GALDERMA RESEARCH & DEVELOPMENT (FR) 2019-04-02 US disclosed
US-20180050992-A1 NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS GALDERMA RESEARCH & DEVELOPMENT (FR) 2018-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180050992-A1 NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS MC1R, CALCRL, BDKRB2 KDM4E 4097/4885HSD17B10 1383/4885MAPK1 2395/4885
US-10246422-B2 Heterocyclic compounds and use thereof in medicine and in cosmetics MC1R, BDKRB2, CCKBR KDM4E 3923/4885HSD17B10 1413/4885MAPK1 2393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.